Article: Nicotinamide Riboside and Metabolic Cofactors Improve Gut Health in Fatty Liver Disease: Preclinical Findings

PrevNext
Digestive/Gut Health Liver Disease Liver Health Preclinical

Nicotinamide Riboside and Metabolic Cofactors Improve Gut Health in Fatty Liver Disease: Preclinical Findings

Synopsis

The gut barrier controls what passes into the body and protects organs like the liver. An unhealthy diet and lifestyle cause gut microbiome imbalances (dysbiosis) and gut barrier damage, which worsen non-alcoholic fatty liver disease (NAFLD). This study tested a combination of metabolic cofactors (betaine, N-acetylcysteine, L-carnitine, nicotinamide riboside) in mice with diet-induced NAFLD. Treatment improved gut structure, reduced gut leakiness, lowered inflammation, and increased gut cell growth. It also changed gut bacteria composition and beneficial short-chain fatty acids. These effects helped slow NAFLD progression by improving gut-liver communication.

Journal

International Journal of Molecular Sciences

Share

Read more

Metabolic Health

Nicotinamide Riboside and Dihydronicotinic Acid Riboside Synergistically Increase NAD+ Levels: Preclinical Findings

SynopsisEukaryotic cells use multiple molecules as NAD+ precursors, but how they work together is unclear. This study identified dihydronicotinic acid riboside (NARH) as a new NAD+ precursor in liv...

Read more
Digestive/Gut Health

Nicotinamide Riboside and Derivatives Alter Intestinal Membrane Function and Gut Microbiome: Preclinical Results

SynopsisResearchers synthesized two new nicotinamide riboside (NR) derivatives—one water-soluble and one oil-soluble—and tested them alongside NR in chick embryos. NR and derivatives altered intest...

Read more